

Annex

Drug Items	2015-16					2016-17					2017-18				
	No. of cases with full subsidy	No. of cases with partial subsidy	Average subsidy amount (\$)	Average patient contribution ¹ (\$)	Total subsidy (\$ million)	No. of cases with full subsidy	No. of cases with partial subsidy	Average subsidy amount (\$)	Average patient contribution ¹ (\$)	Total subsidy (\$ million)	No. of cases with full subsidy	No. of cases with partial subsidy	Average subsidy amount (\$)	Average patient contribution ¹ (\$)	Total subsidy (\$ million)
Samaritan Fund															
Abatacept	28	7	84,855	21,758	2.97	33	10	81,672	13,751	3.51	26	9	89,060	17,146	3.12
Adalimumab	81	39	102,353	16,306	12.28	98	46	100,266	19,448	14.44	110	38	102,589	15,843	15.18
Azacitidine	-	-	-	-	-	25	14	285,696	31,398	11.14	36	15	252,663	46,380	12.89
Bortezomib	61	42	200,945	21,132	20.70	57	29	168,915	35,543	14.53	61	38	178,684	33,012	17.69
Canakinumab	-	-	-	-	-	-	-	-	-	-	0	2	345,851	28,549	0.69
Certolizumab Pegol	-	-	-	-	-	14	6	74,167	19,194	1.48	18	11	74,612	11,341	2.17
Cetuximab	-	-	-	-	-	38	13	77,313	22,479	3.94	22	14	100,550	11,480	3.62
Crizotinib	-	-	-	-	-	-	-	-	-	-	28	19	209,270	27,796	9.84
Dasatinib	62	49	188,583	23,883	20.93	70	60	184,358	26,059	23.96	68	52	187,646	21,539	22.52
Eltrombopag	25	8	95,624	12,531	3.16	26	5	78,018	22,460	2.42	38	10	78,311	7,075	3.76
Erlotinib	9	4	103,553	22,444	1.35	4	2	156,157	2,616	0.94	6	1	101,504	49,519	0.71
Etanercept	141	76	90,409	14,169	19.62	149	71	86,602	16,398	19.05	136	64	89,213	15,886	17.84
Everolimus	-	-	-	-	-	-	-	-	-	-	5	1	156,916	4,124	0.94
Fingolimod	11	6	233,530	30,914	3.97	16	10	238,177	16,182	6.19	19	12	238,101	16,275	7.38

¹ This refers to the average patient contribution in cases with partial subsidy.

	2015-16					2016-17					2017-18				
Drug Items	No. of cases with full subsidy	No. of cases with partial subsidy	Average subsidy amount (\$)	Average patient contribution ¹ (\$)	Total subsidy (\$ million)	No. of cases with full subsidy	No. of cases with partial subsidy	Average subsidy amount (\$)	Average patient contribution ¹ (\$)	Total subsidy (\$ million)	No. of cases with full subsidy	No. of cases with partial subsidy	Average subsidy amount (\$)	Average patient contribution ¹ (\$)	Total subsidy (\$ million)
Gefitinib	4	3	135,285	48,788	0.95	4	3	115,169	38,096	0.81	4	3	68,692	40,458	0.48
Golimumab	81	40	87,805	10,686	10.62	90	50	87,133	11,628	12.20	101	43	88,952	12,607	12.81
Growth hormone	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Imatinib	208	150	202,731	23,320	72.57	218	154	124,285	27,263	46.23	145	70	158,118	26,867	34.00
Infliximab	30	13	106,409	9,000	4.58	39	7	110,415	23,985	5.08	30	8	113,137	23,189	4.30
Interferon	2	1	184,971	4,097	0.55	0	0	0	0	0	0	2	198,350	13,276	0.40
Lenalidomide	17	5	131,764	20,685	2.90	30	9	124,292	23,563	4.85	33	16	152,066	24,947	7.45
Natalizumab	0	1	234,755	12,824	0.23	0	1	244,358	3,221	0.24	0	0	0	0	0
Nilotinib	50	54	230,194	26,716	23.94	57	58	223,309	23,213	25.68	63	51	237,425	28,602	27.06
Plerixafor	-	-	-	-	-	5	1	93,218	4,991	0.56	16	2	82,167	4,345	1.48
Rituximab	152	104	81,291	28,909	20.81	179	93	86,351	34,204	23.49	167	104	80,962	32,867	21.94
Temozolomide	34	12	55,056	9,109	2.53	34	19	58,208	18,375	3.08	33	15	65,234	18,068	3.13
Tocilizumab	70	32	72,863	11,116	7.44	87	33	66,793	19,271	8.02	85	39	65,913	17,841	8.17
Trastuzumab	264	260	162,766	42,500	85.29	301	283	171,588	45,831	100.21	241	248	187,433	52,133	91.65
Ustekinumab	0	1	110,320	2,000	0.11	2	2	81,861	64,890	0.33	4	2	80,068	57,932	0.48
Community Care Fund Medical Assistance Programme (First Phase Programme)															
Abiraterone	-	-	-	-	-	-	-	-	-	-	19	11	138,140	44,955	4.15
Afatinib	-	-	-	-	-	12	8	134,625	23,901	2.69	32	16	130,655	36,363	6.27
Bendamustine	-	-	-	-	-	2	0	228,972	0	0.46	6	2	250,488	12,337	2.00

	2015-16					2016-17					2017-18				
Drug Items	No. of cases with full subsidy	No. of cases with partial subsidy	Average subsidy amount (\$)	Average patient contribution ¹ (\$)	Total subsidy (\$ million)	No. of cases with full subsidy	No. of cases with partial subsidy	Average subsidy amount (\$)	Average patient contribution ¹ (\$)	Total subsidy (\$ million)	No. of cases with full subsidy	No. of cases with partial subsidy	Average subsidy amount (\$)	Average patient contribution ¹ (\$)	Total subsidy (\$ million)
Bevacizumab	10	4	94,879	17,061	1.33	7	6	79,625	33,558	1.04	22	21	145,170	20,242	6.24
Cetuximab	18	12	75,189	21,066	2.26	10	8	18,769	8,283	0.34	-	-	-	-	-
Enzalutamide	-	-	-	-	-	-	-	-	-	-	21	9	139,721	39,210	4.19
Erlotinib	174	124	115,198	35,648	34.33	219	128	116,228	32,102	40.33	247	136	94,726	26,052	36.28
Gefitinib	309	189	132,223	26,915	65.85	341	165	109,289	28,627	55.30	341	145	86,909	20,703	42.24
Lapatinib	36	30	61,038	5,058	4.03	67	29	63,116	6,612	6.06	70	40	63,808	12,037	7.02
Pazopanib	18	9	121,913	36,445	3.29	33	12	130,736	37,684	5.88	31	19	103,162	31,254	5.16
Pegylated liposomal Doxorubicin	36	8	59,385	29,780	2.61	23	18	63,834	23,166	2.62	41	12	65,423	24,040	3.47
Pemetrexed	242	108	61,731	19,842	21.61	273	118	62,478	20,300	24.43	294	56	20,028	6,134	7.01
Pertuzumab	-	-	-	-	-	-	-	-	-	-	17	31	445,060	69,790	21.36
Sorafenib	200	82	53,656	11,667	15.13	196	94	48,898	12,195	14.18	212	88	46,906	10,115	14.07
Sunitinib	46	23	92,108	38,558	6.35	35	25	106,868	18,887	6.41	46	15	114,658	26,454	7.00
Trastuzumab	-	-	-	-	-	-	-	-	-	-	6	3	177,704	5,256	1.60
Vemurafenib	-	-	-	-	-	0	2	330,696	95,304	0.66	1	2	241,203	64,195	0.72
Community Care Fund “Subsidy for Eligible Patients to Purchase Ultra-expensive Drugs (Including Those for Treating Uncommon Disorders)” ²															
Eculizumab	-	-	-	-	-	-	-	-	-	-	3	6	3,953,510	207,462	35.58

² This Community Care Fund medical assistance programme was introduced in August 2017.